Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation

被引:57
作者
Eaton, Bree R. [1 ,2 ]
Gebhardt, Brian [1 ,2 ]
Prabhu, Roshan [1 ,2 ]
Shu, Hui-Kuo [1 ,2 ]
Curran, Walter J., Jr. [1 ,2 ]
Crocker, Ian [1 ,2 ]
机构
[1] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源
RADIATION ONCOLOGY | 2013年 / 8卷
关键词
Hypofractionated; Radiosurgery; Brain; Metastases; INTENSITY-MODULATED RADIOTHERAPY; STEREOTACTIC RADIOTHERAPY; NONINVASIVE FIXATION; SINGLE; IRRADIATION; TUMORS; TRIAL; SKULL;
D O I
10.1186/1748-717X-8-135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hypofractionated Radiosurgery (HR) is a therapeutic option for delivering partial brain radiotherapy (RT) to large brain metastases or resection cavities otherwise not amenable to single fraction radiosurgery (SRS). The use, safety and efficacy of HR for brain metastases is not well characterized and the optimal RT dose-fractionation schedule is undefined. Methods: Forty-two patients treated with HR in 3-5 fractions for 20 (48%) intact and 22 (52%) resected brain metastases with a median maximum dimension of 3.9 cm (0.8-6.4 cm) between May 2008 and August 2011 were reviewed. Twenty-two patients (52%) had received prior radiation therapy. Local (LC), intracranial progression free survival (PFS) and overall survival (OS) are reported and analyzed for relationship to multiple RT variables through Cox-regression analysis. Results: The most common dose-fractionation schedules were 21 Gy in 3 fractions (67%), 24 Gy in 4 fractions (14%) and 30 Gy in 5 fractions (12%). After a median follow-up time of 15 months (range 2-41), local failure occurred in 13 patients (29%) and was a first site of failure in 6 patients (14%). Kaplan-Meier estimates of 1 year LC, intracranial PFS, and OS are: 61% (95% CI 0.53 - 0.70), 55% (95% CI 0.47 - 0.63), and 73% (95% CI 0.65 - 0.79), respectively. Local tumor control was negatively associated with PTV volume (p = 0.007) and was a significant predictor of OS (HR 0.57, 95% CI 0.33 - 0.98, p = 0.04). Symptomatic radiation necrosis occurred in 3 patients (7%). Conclusions: HR is well tolerated in both new and recurrent, previously irradiated intact or resected brain metastases. Local control is negatively associated with PTV volume and a significant predictor of overall survival, suggesting a need for dose escalation when using HR for large intracranial lesions.
引用
收藏
页数:7
相关论文
共 24 条
[11]   Hypofractionated stereotactic radiotherapy for brain metastases [J].
Fahrig, Antje ;
Ganslandt, Oliver ;
Lambrecht, Ulrike ;
Grabenbauer, Gerhard ;
Kleinert, Gabriele ;
Sauer, Rolf ;
Hamm, Klaus .
STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 (11) :625-630
[12]   Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases [J].
Giubilei, Cesare ;
Ingrosso, Gianluca ;
D'Andrea, Marco ;
Benassi, Michaela ;
Santoni, Riccardo .
JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (02) :207-212
[13]   Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases [J].
Kondziolka, D ;
Patel, A ;
Lunsford, LD ;
Kassam, A ;
Flickinger, JC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02) :427-434
[14]   Hypofractionated Stereotactic Radiotherapy for the Treatment of Brain Metastases [J].
Kwon, Alexander K. ;
DiBiase, Steven J. ;
Wang, Brian ;
Hughes, Samuel L. ;
Milcarek, Barry ;
Zhu, Yunping .
CANCER, 2009, 115 (04) :890-898
[15]   Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases [J].
Lindvall, P ;
Bergström, P ;
Löfroth, PO ;
Henriksson, R ;
Bergenheim, AT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05) :1460-1466
[16]   The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline [J].
Linskey, Mark E. ;
Andrews, David W. ;
Asher, Anthony L. ;
Burri, Stuart H. ;
Kondziolka, Douglas ;
Robinson, Paula D. ;
Ammirati, Mario ;
Cobbs, Charles S. ;
Gaspar, Laurie E. ;
Loeffler, Jay S. ;
McDermott, Michael ;
Mehta, Minesh P. ;
Mikkelsen, Tom ;
Olson, Jeffrey J. ;
Paleologos, Nina A. ;
Patchell, Roy A. ;
Ryken, Timothy C. ;
Kalkanis, Steven N. .
JOURNAL OF NEURO-ONCOLOGY, 2010, 96 (01) :45-68
[17]   The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases [J].
Mehta, MP ;
Tsao, MN ;
Whelan, TJ ;
Morris, DE ;
Hayman, JA ;
Flickinger, JC ;
Mills, M ;
Rogers, CL ;
Souhami, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (01) :37-46
[18]   Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases [J].
Narayana, Ashwatha ;
Chang, Jenghwa ;
Yenice, Kamil ;
Chan, Kelvin ;
Lymberis, Stella ;
Brennan, Cameron ;
Gutin, Philip H. .
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY, 2007, 85 (2-3) :82-87
[19]   Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors [J].
Ogura, Kengo ;
Mizowaki, Takashi ;
Ogura, Masakazu ;
Sakanaka, Katsuyuki ;
Arakawa, Yoshiki ;
Miyamoto, Susumu ;
Hiraoka, Masahiro .
JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (02) :425-432
[20]   Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy [J].
Park, Clint ;
Papiez, Lech ;
Zhang, Shichuan ;
Story, Michael ;
Timmerman, Robert D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (03) :847-852